Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab Versus Aflibercept for Macular Edema Secondary to Non-ischemic Central Retinal Vein Occlusion in Young Adult Patients.

NCT05282420 is registered in ClinicalTrials.gov with South Valley University as lead sponsor.

NCT NCT05282420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05282420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab Versus Aflibercept for Macular Edema Secondary to Non-ischemic Central Retinal Vein Occlusion in Young Adult Patients.
Lead sponsor
South Valley University
Phase
Phase 4
Overall status
Unknown status
Start date
February 1, 2021
Completion date
May 31, 2022
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-ischemic central retinal vein occlusion with macular edema